Stocks of Heron Therapeutics Inc (HRTX) are poised to climb above their peers

With 1.53 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.98 million shares. The 52-week range on HRTX shows that it touched its highest point at $3.93 and its lowest point at $1.04 during that stretch. It currently has a 1-year price target of $6.25. Beta for the stock currently stands at 1.38.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HRTX was down-trending over the past week, with a drop of -3.24%, but this was up by 29.19% over a month. Three-month performance surged to 102.54% while six-month performance rose 35.03%. The stock lost -6.64% in the past year, while it has gained 56.21% so far this year. A look at the trailing 12-month EPS for HRTX yields -0.09 with Next year EPS estimates of 0.05. For the next quarter, that number is -0.01. This implies an EPS growth rate of 50.00% for this year and 218.52% for next year.

Float and Shares Shorts:

At present, 152.13 million HRTX shares are outstanding with a float of 151.00 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HRTX since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.12397 being high and -$0.13399 being low. For HRTX, this leads to a yearly average estimate of -$0.12887. Based on analyst estimates, the high estimate for the next quarter is $0.0 and the low estimate is -$0.02. The average estimate for the next quarter is thus -$0.01.